The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The backing comes as influenza remains a persistent public health burden
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The regulatory decision follows promising results from RIVER-81
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
